NEW ORLEANS—Co-investigator Saibil Kar, MD, of Cedars-Sinai Medical Center in Los Angeles, explained the two-year follow-up results of the EVEREST II randomized controlled trial, which compared the results observed at 12 months to determine the durability of outcomes through 24 months for the device and control groups using the MitraClip device (Abbott) or surgical repair for patients with mitral regurgitation. The late breaking clinical trial was presented April 4 at the American College of Cardiology (ACC) Scientific Sessions.
Kate Hanneman, MD, explains why many vendors and hospitals want to lower radiology's impact on the environment. "Taking steps to reduce the carbon footprint in healthcare isn’t just an opportunity," she said. "It’s also a responsibility."
Philips introduced a new CT system at ECR aimed at the rapidly growing cardiac CT market, incorporating numerous AI features to optimize workflow and image quality.